drugset / Trial / NCT03809156
Upfront Combination Pulmonary Arterial Hypertension Therapy
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of first-line combination therapy using riociguat with ambrisentan in patients with Pulmonary Arterial Hypertension (PAH).
Timeline
- Start
- 2016-04-26
- Primary completion
- 2020-12-31
- Completion
- 2021-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ambrisentan | Small molecule | — | Oral |
| Subject | Riociguat | Other / unclassified | — | Oral |